{"news_desk": "SundayBusiness", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By GRETCHEN MORGENSON", "person": [{"rank": 1, "role": "reported", "firstname": "Gretchen", "organization": "", "lastname": "MORGENSON"}]}, "abstract": "Gretchen Morgenson Fair Game column examines lawsuit claiming French pharmaceutical firm Sanofi favored its own multiple sclerosis drug over that of Genzyme, which it bought in 2011, to dodge $3.8 billion in payments to Genzyme shareholders.", "type_of_material": "News", "word_count": "1020", "lead_paragraph": "A lawsuit claims that a giant French pharmaceutical favored its own multiple sclerosis treatment to avoid making a huge payout.", "pub_date": "2015-11-15T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "After Merger, Two Competing Drugs and Billion-Dollar Questions", "content_kicker": "Fair Game", "print_headline": "One Merger, Two Drugs, Millions Lost", "kicker": "Fair Game"}, "snippet": "A lawsuit claims that a giant French pharmaceutical favored its own multiple sclerosis treatment to avoid making a huge payout.", "multimedia": [{"height": 126, "url": "images/2015/11/15/business/gret-web1/gret-web1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/11/15/business/gret-web1/gret-web1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 424, "url": "images/2015/11/15/business/gret-web1/gret-web1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "424", "xlarge": "images/2015/11/15/business/gret-web1/gret-web1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/11/15/business/gret-web1/gret-web1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/11/15/business/gret-web1/gret-web1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/11/15/business/after-merger-two-competing-drugs-and-billion-dollar-questions.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Genzyme Corp", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Sanofi SA", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Suits and Litigation (Civil)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "5", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "6", "is_major": "Y", "value": "Multiple Sclerosis", "name": "subject"}], "blog": [], "_id": "5645eddd38f0d8244c637543", "source": "The New York Times"}